STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump secured a $27 billion drug‑development investment from Regeneron and a $225 price for Praluent on TrumpRx, completing the White House’s 17‑deal pharma pricing push.
- Regeneron received FDA approval for Otarmeni, the first gene‑therapy greenlit under the National Priority Voucher program.
- Todd Blanche signed an order moving state‑licensed medical marijuana from Schedule I to Schedule III, granting tax breaks and easing research restrictions.
Why it matters: U.S. patients and Medicaid stand to save on Praluent and future drugs, while Regeneron gains a $27 billion domestic R&D pipeline; the Schedule III reclassification lowers barriers for cannabis research, potentially spurring new therapies.
